Not Yet RecruitingNot Applicable

DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community

Spain250 participantsStarted 2026-04-27

Plain-language summary

The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona. It will also examine how factors such as age, income, education, and health conditions may affect these levels. In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care. The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.

Who can participate

Age range

50 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA * Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent * Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context. * Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling. * Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant. EXCLUSION CRITERIA * Cognitive decline defined by CDR\>0. * Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life * Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study. * Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc). * Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or h…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Plasma levels of Alzheimer's disease blood-based biomarkers across ethnic groups

Timeframe: Through study completion, an average of 1 year

Trial details

NCT IDNCT07521722

SponsorBarcelonabeta Brain Research Center, Pasqual Maragall Foundation

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-27

Contact for this trial

Gianmarco Iaccarino

+34‭ 933263190 giaccarino@barcelonabeta.org

View on ClinicalTrials.gov More Alzheimer Disease trials